CureVac Files Patent Infringement Lawsuit Against BioNTech Over Covid Vaccine
05 Luglio 2022 - 2:01PM
Dow Jones News
By Jaime Llinares Taboada
CureVac NV said Tuesday that it has filed a patent infringement
lawsuit in a German court against BioNTech SE.
The Nasdaq-listed biopharmaceutical company said the lawsuit
seeks fair compensation for infringement of a portfolio of
CureVac's intellectual property rights which are used in BioNTech
and Pfizer Ltd.'s mRNA COVID-19 vaccine.
CureVac said its IP portfolio protects inventions essential to
the design and development of BioNTech's vaccine.
"Accordingly, CureVac's intellectual property rights need to be
acknowledged and respected in the form of a fair compensation to
reinvest into the further advancement of mRNA technology and the
ongoing development of new classes of life saving medicines," the
company said.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com;
@JaimeLlinaresT
(END) Dow Jones Newswires
July 05, 2022 07:46 ET (11:46 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Grafico Azioni CureVac NV (NASDAQ:CVAC)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni CureVac NV (NASDAQ:CVAC)
Storico
Da Giu 2023 a Giu 2024
